nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A multipronged approach to tackle RSV-associated disease
|
The Lancet Respiratory Medicine, |
|
|
9 |
10 |
p. 1077 |
artikel |
2 |
Are changes in practice a cause of the rising burden of bronchiolitis for paediatric intensive care units?
|
Linssen, Rosalie S |
|
|
9 |
10 |
p. 1094-1096 |
artikel |
3 |
Azithromycin: can its benefit be ruled out in mild COVID-19?
|
Rodríguez-Molinero, Alejandro |
|
|
9 |
10 |
p. 1079-1081 |
artikel |
4 |
Azithromycin for mild-to-moderate COVID-19
|
Patel, Jigar |
|
|
9 |
10 |
p. e99 |
artikel |
5 |
Azithromycin for mild-to-moderate COVID-19 – Authors' reply
|
Hinks, Timothy S C |
|
|
9 |
10 |
p. e100-e101 |
artikel |
6 |
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
|
Hinks, Timothy S C |
|
|
9 |
10 |
p. 1130-1140 |
artikel |
7 |
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
|
Busse, William W |
|
|
9 |
10 |
p. 1165-1173 |
artikel |
8 |
Circulation of influenza, RSV, and SARS-CoV-2: an uncertain season ahead
|
Burki, Talha Khan |
|
|
9 |
10 |
p. e103 |
artikel |
9 |
Correction to Lancet Respir Med 2021; 9: 1130–40
|
|
|
|
9 |
10 |
p. e102 |
artikel |
10 |
Correction to Lancet Respir Med 2021; published online Sept 1. https://doi.org/10.1016/S2213-2600(21)00331-3
|
|
|
|
9 |
10 |
p. e102 |
artikel |
11 |
COVID-19 vaccines: addressing hesitancy in young people with allergies
|
Abrams, Elissa M |
|
|
9 |
10 |
p. 1090-1092 |
artikel |
12 |
Do B cells rather than eosinophils drive chronic rhinosinusitis with nasal polyps?
|
Kariyawasam, Harsha H |
|
|
9 |
10 |
p. e97 |
artikel |
13 |
Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial
|
Ruffles, Tom J C |
|
|
9 |
10 |
p. 1121-1129 |
artikel |
14 |
GINA 2021: the missing pieces in the childhood asthma puzzle
|
Santamaria, Francesca |
|
|
9 |
10 |
p. e98 |
artikel |
15 |
Increasing utility of FeNO as a biomarker of type-2 inflammation in severe asthma
|
Chung, Kian Fan |
|
|
9 |
10 |
p. 1083-1084 |
artikel |
16 |
Interstitial lung diseases: quo vadis?
|
Kreuter, Michael |
|
|
9 |
10 |
p. 1084-1087 |
artikel |
17 |
Managing chronic wet cough in children: another piece of the puzzle
|
Gilchrist, Francis J |
|
|
9 |
10 |
p. 1078-1079 |
artikel |
18 |
Mepolizumab for chronic rhinosinusitis with nasal polyps
|
Brusselle, Guy G |
|
|
9 |
10 |
p. 1081-1082 |
artikel |
19 |
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Han, Joseph K |
|
|
9 |
10 |
p. 1141-1153 |
artikel |
20 |
Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines
|
Jankowich, Matthew |
|
|
9 |
10 |
p. 1185-1191 |
artikel |
21 |
Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease
|
Podolanczuk, Anna J |
|
|
9 |
10 |
p. 1087-1089 |
artikel |
22 |
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
|
Lu, Shun |
|
|
9 |
10 |
p. 1154-1164 |
artikel |
23 |
Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop
|
Arrigo, Mattia |
|
|
9 |
10 |
p. 1192-1202 |
artikel |
24 |
Pathological disease in the lung periphery after acute COVID-19
|
Siddiqui, Salman |
|
|
9 |
10 |
p. 1089-1090 |
artikel |
25 |
Perplexing mortality data from triple therapy trials in COPD – Author's reply
|
Martinez, Fernando J |
|
|
9 |
10 |
p. e96 |
artikel |
26 |
Respiratory syncytial virus and asthma: untying the Gordian knot
|
Hartert, Tina V |
|
|
9 |
10 |
p. 1092-1094 |
artikel |
27 |
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
|
Ruckwardt, Tracy J |
|
|
9 |
10 |
p. 1111-1120 |
artikel |
28 |
Story from a survivor of tuberculosis
|
Linton, Emma |
|
|
9 |
10 |
p. 1098-1100 |
artikel |
29 |
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study
|
McDowell, P Jane |
|
|
9 |
10 |
p. 1174-1184 |
artikel |
30 |
Tobacco industry capitalises on the COVID-19 pandemic
|
Burki, Talha Khan |
|
|
9 |
10 |
p. 1097-1098 |
artikel |
31 |
Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study
|
Avidan, Alexander |
|
|
9 |
10 |
p. 1101-1110 |
artikel |